With so many weight loss medications on the market, it's easy to feel overwhelmed by the options. From brand-name heavy ...
Eli Lilly announces $15 billion share buyback plan and 15% dividend boost amidst mixed technical signals. Investors are ...
With Eli Lilly's diabetes and obesity products Mounjaro and Zepbound booming in popularity, the drugmaker finds itself in a ...
Eli Lilly and Co. approved a program to buy back as much as $15 billion of its own shares amid rapid growth fueled in part by ...
Zepbound outperformed Wegovy for weight loss in a new clinical trial funded by Eli Lilly & Co., Zepbound's maker.
CBS News reports that workplace violence at Allina Health's Abbott Northwestern Hospital has led to more than $83,000 in fines over the past year. Other news from the health industry is on the demand ...
Eli Lilly just shared some new information. That data suggests it has an advantage against Novo Nordisk in a key market.
It didn’t take long for the shine to come off one of biotech’s recent IPO success stories, with BioAge Labs scrapping a phase ...
Eli Lilly is spending another $3 billion to bulk up manufacturing as the drugmaker seeks to stoke production of some blockbuster drugs and future products.
Lilly announces a $3B expansion in Wisconsin to boost production of weight loss drugs and strengthen its position in the ...
Weight-loss drugs like Ozempic seem like a miracle. But they've also created a gold rush for online scammers and hucksters.
As demand for obesity drugs like Wegovy, Zepbound, Mounjaro and Ozempic, outpaces supply, online scams are rising, according ...